Biohit suspends trial aiming at H. pylori eviction

Biohit Oyj Stock Exchange Release February 18, 2014 at 10:45 am local time (EET)

A clinical study launched by Biohit to examine the ability of BioAcetium to help treat Helicobacter pylori infection has not produced clear-cut results. The BioAcetium Study has been suspended until further notice, whilst Biohit prioritizes other clinical studies.

The most essential reason for suspending the clinical study is the increased resistance of helicobacter strains to different therapies. The resistance to treatment by H. pylori strains varies geographically, which means that the treatment results in one country are not directly applicable elsewhere.

Additional information:

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com